Microfluidic technologies for the synthesis and manipulation of biomimetic membranous nano-assemblys

Colin P. Pilkington, John M. Seddon and Yuval Elani*

Microfluidics has been proposed as an attractive alternative to conventional bulk methods used in the generation of self-assembled biomimetic structures, particularly where there is a desire for more scalable production. The approach also allows for greater control over the self-assembly process, and parameters such as particle architecture, size, and composition can be finely tuned. Microfluidic techniques used in the generation of microscale assemblies (giant vesicles and higher-order multi-compartment assemblies) are fairly well established. These tend to rely on microdroplet templation, and the resulting structures have found use as compartmentalised motifs in artificial cells. Challenges in generating sub-micron droplets have meant that reconfiguring this approach to form nano-scale structures is not straightforward. This is beginning to change however, and recent technological advances have instigated the manufacture and manipulation of an increasingly diverse repertoire of biomimetic nano-assemblys, including liposomes, polymersomes, hybrid particles, multi-lamellar structures, cubosomes, hexosomes, nanodiscs, and virus-like particles. The following review will discuss these higher-order self-assembled nanostructures, including their biochemical and industrial applications, and techniques used in their production and analysis. We suggest ways in which existing technologies could be repurposed for the enhanced design, manufacture, and exploitation of these structures and discuss potential challenges and future research directions. By compiling recent advances in this area, it is hoped we will inspire future efforts toward establishing scalable microfluidic platforms for the generation of biomimetic nanoparticles of enhanced architectural and functional complexity.

Introduction

Bio-inspired membranous structures have a wide range of potential applications, most notably as simplified chassis for the study of cellular features and as functional soft-matter
particles that can act as carriers for therapeutic molecules. They are also of interest to those working in the field of bottom-up synthetic biology, concerned with the design, synthesis, and manipulation of cell-like objects sometimes termed artificial cells. Membranous structures of varied size and phase behaviour (referring to the intrinsic order and morphology of said structures) have been produced, mimicking the basic architecture of living cells.1–3 Drawing inspiration from biological sources, many cell-like behaviours have been successfully modelled, including motility and intercellular communication.4–6 These biomimetic, synthetically derived structures have also been used to better understand cell fusion events and small molecule/membrane interactions.7,8 Their modular design and capacity to incorporate functional biomolecular componentry has allowed researchers to expand their use to specialised drug delivery,9,10 biosensing,11 controlled content release,12 protein synthesis,13,14 energy production,15 and most recently as carriers of immunotherapeutic mRNA strands with potential to aid the global effort against COVID-19.16,17 Controllable generation of these structures is key to their success, something that has been addressed via the integration of microfluidic methods. However, in contrast to macroscale membrane assemblies,18 existing examples of nano-scale cell-like objects generated by microfluidics tend to show limited compositional and architectural diversity, which has restricted their technological potential. We know from biology that architectural complexity gives rise to functional and behavioural complexity. Indeed, this is one of the key drivers behind bottom-up synthetic biology. Widening the applicability of membranous particles is therefore reliant on the generation of structures more elaborate than simple uni-compartment bilayer capsules. In this review we highlight some of the effort that has been made toward establishing microfluidic methods capable of accessing and leveraging higher-order nano-scale biomimetic particles.

Yuval Elani is a UKRI Future Leaders Fellow and Lecturer at the Department of Chemical Engineering at Imperial College London. He co-Founded the fabricCELL centre for artificial cell research and is co-Director of the Membrane Biophysics Platform. Yuval was born in South Africa and also lived in Israel and the UK. His undergraduate training was at Cambridge, which was followed by a PhD and a series of independent fellowships at Imperial. His interests are in the development of technologies for engineering artificial cells for clinical and industrial applications. He has expertise in bottom-up synthetic biology, microfluidics and membrane chemical biology.

To encourage future work, we also suggest ways in which other platforms may be adapted to better include these structures. The nano-assemblies we cover (summarised in Fig. 1) were chosen on the basis of their (i) biological relevance and (ii) deviation from the current structural and compositional norms of bottom-up synthetic biology.

Self-assembly

Before discussing the main characteristics and generation methods associated with higher-order biomimetic nanostructures, it is important to first outline the underlying principles behind their self-assembly. Here, the process can be considered a generalised grouping together of smaller components (molecules or protein subunits) forming larger structures with varying degrees of order. For the purposes of this paper, these components are naturally derived or at least bio-mimetic in some way, distinguishing their nano-assemblies from inorganic nanoparticles that have been covered extensively elsewhere (gold particles, silica colloids etc.).79 Nanostructures composed of amphiphilic small molecules (molecules with both hydrophilic and hydrophobic portions – either lipids or block copolymers) are predominantly stabilised by hydrophobic interactions in a polar environment. Amphiphiles are thought of in terms of their molecular shape, and grouped according to their geometric packing parameter $P$ (see Fig. 2A):

$$P = \frac{\nu}{a_0 l_c}$$

where $\nu$, $a_0$ and $l_c$ are the molecular volume, the cross-sectional area of the polar head-group, and the length of the hydrophobic chain respectively.20–22 $P$ is dependent on the intrinsic molecular properties of a given amphiphile and is most often used for lipid systems. Its use can also be extended to polymeric building blocks, though their geometries are less fixed, owing to comparatively higher internal degrees of molecular freedom.23 Modelling the shape of amphiphiles in this way helps to visualise the interfacial curvatures of their aggregates, described by the mean curvature ($H$) and Gaussian curvature ($K$) below, where $c_1$ and $c_2$...
are reciprocals of the radii of curvature ($R_1$ and $R_2$; Fig. 2B) of an interface.

\[ K = \frac{c_1 c_2}{R_1 R_2} \]  
\[ H = \frac{c_1 + c_2}{2} \]

There is an energetic cost associated with packing hydrophobic portions of amphiphiles into self-assembled aggregates ($\gamma_p$), a process that is entropically driven by the expulsion of free water molecules. The surfaces generated also feature stored elastic free energy $\gamma_e$ given by the Helfrich equation below:

\[ \gamma_e = 2\kappa (H - H_0)^2 + \kappa_c K \]

where $\kappa$ and $\kappa_c$ represent the mean and Gaussian curvature moduli, respectively, measures of the energetic burden associated with changing the mean and Gaussian curvatures of a given bilayer. The sum of $\gamma_e$, $\gamma_p$ and a generalised term for the energy of molecular interactions (found to be mostly negligible in lipidic systems) contributes to the total free energy of the assembly ($\gamma_f$):

\[ \gamma_f = \gamma_e + \gamma_p + \gamma_{\text{inter}} \]

A consideration of $\gamma_f$ provides a thermodynamic rationale for how environmental conditions such as temperature, pressure and solvent type affect the phase behaviour of amphiphilic assemblies. As conditions change, so too do the preferred geometries of amphiphiles, and the resultant curvatures and phase behaviours of their aggregates. These phases are generally grouped according to their relative values of $H$ and $K$, each with distinct topologies and varying degrees of liquid crystalline periodicity. Polymer assemblies are governed by the same thermodynamic principles, though their morphologies can differ significantly when compared to lipid systems.

Both the physical properties and potential applications of a bio-inspired nano-assembly will vary from phase to phase, highlighting the need to maintain considerable control over the experimental parameters governing phase behaviour.

Where protein subunits are concerned (as is the case for virus-like particles) other forces such as H-bonding and covalent bonds control their self-assembly into nanostructures. Their formation is actively mediated by the cell-machinery of genetically engineered organisms, the thermodynamic principles of which will not be covered in this paper.

**Microfluidics: advantages & current limiting factors**

Microfluidics has revolutionised experimental design across many scientific disciplines. Through the manipulation of small volumes of liquids at low Reynolds numbers, entire laboratories have been miniaturised to fit on millimetre-sized chips, paving the way toward higher throughput and less wasteful scientific research. For bottom-up synthetic biology in particular, the use of microfluidics has shown great promise, whether in finely tuning the self-assembly of biologically inspired objects or in the subsequent application of those objects as “smart materials”. Microfluidic platforms have enabled researchers to achieve enhanced control over experimental parameters such as monomer composition, kinetics of self-assembly and particle morphology. However, microfluidics has tremendous untapped potential for the design, synthesis and manipulation of more complex bio-inspired materials, as most existing work has dealt with structures on the micrometre size range, rendering them unsuitable for a variety of industrial and medical applications.

Existing “bulk” formation methods have worked well where nano-systems remain relatively simple. Most often used is the rehydration of a dried amphiphile film in a suitable polar medium, followed by agitation to promote self-assembly. The structures formed are extruded through filters of defined pore-size to achieve relatively monodisperse nano-sized particles. High-powered probe sonication and high-shear mixing achieve a similar result to extrusion, though both are often deemed unsuitable for use with sensitive biological material. In accessing more complex, higher-order structures, precise control over the self-assembly process is required, beyond the capability of these bulk methods. Though it is possible to produce particles of a narrow size distribution en masse, this can only be achieved either through secondary preparatory steps or by high energy input. As such, microfluidics has presented a superior alternative, bestowing:

- high generation and experimental throughput.
- excellent size control.
- low energy costs, more efficient use of reagents.
- and, most importantly for higher-order supramolecular structure formation, an enhanced control over reaction conditions, such as temperature and solute concentration.

Droplet microfluidics has been used extensively in micro-scale bottom-up synthetic biology, providing spherical templates around which the biomimetic structures are encouraged to assemble. This approach has been used to generate giant unilamellar vesicles (GUVs) and GUVs with multiple organelle-like sub-compartments called vesosomes. Though useful as bio-inspired synthetic vessels, in which enzymatic reactions and other biochemical pathways can be reproducibly...
mimicked, droplet-templated approaches have two key drawbacks:

(i) Size constraints: droplets often have diameters above 10 μm. The generation of droplets in the sub-micron regime can be difficult to achieve, requiring very high, impractical flow rates (in the case of cross-flow junction droplet generators) or nano-scale microfluidic chip features that are beyond the scope of existing lithographic fabrication techniques.\(^{31-33,39}\)

(ii) Phases of lipidic/polymeric assemblies: biomimetic structures produced by droplet microfluidics are confined to lamellar phases only.\(^{18,31-33,39}\)

As a result, researchers have focused on continuous flow microfluidic methods to generate nano-assemblies (<150 nm), most notably microfluidic hydrodynamic focusing (MHF; see Fig. 3 for overview). Self-assembly in this case is mediated by diffusion-dominated mass transport.\(^{31}\) The technique has been used to generate nano-sized unilamellar lipid vesicles, though its potential for producing multi-compartment/architecturally and functionally diverse nano-assemblies has yet to be investigated in full. It presents an attractive alternative to existing bulk methods for nano-assembly preparation, particularly within an industrial setting, capable of generating structures of very low polydispersity indices (PDIs) at a high production rate. There are examples of it being used to produce polymersomes and to generate non-lamellar liposomal nanoparticles, as will be highlighted in later sections.\(^{23,43,44}\) An appropriate concentration of amphiphile dissolved in a water–miscible solvent is injected into a central microfluidic channel and the stream compressed into a continuous flow regime by two adjacent channels containing aqueous buffer. A diffusion gradient is established between the two solvents, along which amphiphiles reach their respective solubility thresholds and begin to nucleate and self-assemble. The process is governed by diffusion-dominated mass transport, and the average mixing time of the streams described by eqn (6).

\[
\tau_{\text{mix}} \propto \frac{x^2}{D}
\]

where \(x\) and \(D\) are the diffusion length and diffusion coefficient of a given amphiphile respectively.\(^{44,45}\) By adjusting the flow rate ratio (FRR) between the aqueous and non-aqueous streams it is possible to tune the cross-sectional area of the central stream, and consequently control the diffusion length along which amphiphiles self-assemble into nanostructures. Particles produced in this way have low dispersity indices, the central stream shielded from adopting the parabolic fluid velocity profile characteristic of a no-slip boundary condition.\(^{44}\) A decreasing FRR value is roughly proportional to an increase in nanoparticle size. Several factors affect experimental reproducibility, and care is taken to avoid the distortion of the focused stream at higher flow rates and Re numbers. This is generally achieved by manipulating the design of the focusing junction and by introducing an appropriate surface treatment, reducing the “cusp”ing of focused streams i.e. maintaining a relatively uniform diffusion length throughout the post-junction channel.\(^{44}\) The length of microfluidic channel is often optimised to allow for complete diffusion of amphiphiles, minimising the uncontrolled formation of amphiphilic aggregates off-chip.\(^{44-46}\) It is a robust and versatile technique, and the process can be easily modified by introducing secondary flow regimes and additional microfluidic features, making it a particularly attractive starting point toward the development of more architecturally complex artificial cell chassis and soft-matter particles.\(^{43,46}\)

The method can be readily adapted to fit industrial requirements of scale and throughput. An impressive article by Carugo et al. demonstrated liposome production at concentrations suitable for most drug delivery applications (typically ranging between 5 and 15 mg ml\(^{-1}\)) with total flow rates of up to 18 ml min\(^{-1}\), using chips with channel dimensions on the millimetre scale.\(^{41}\) Further efforts to scale-up MHF have led to the development of a technique termed “vertical flow focusing” (VFF), able to produce nano-sized liposomes two orders of magnitude faster than traditional MHF.\(^{47}\) The chip design extends channel dimensions along the z-axis only: channels are deep (5 mm) and narrow (50 μm). This minor change was observed to significantly increase the throughput of generated liposomes and further minimise the unwanted effects of a no-slip boundary condition on the process of self-assembly.\(^{47}\) Both examples successfully optimise the microfluidic method without jeopardising its main asset: the continuous and controllable generation of nano-assemblies. Future devices that incorporate parallelized MHF junctions are also expected to enhance throughput, taking inspiration from the mass production of emulsions via droplet microfluidics.\(^{48,49}\) This has been touched on by Carugo et al., who suggest the use of “off-the-shelf” components for parallel liposome generation, such as a four-way tubing splitter.\(^{41}\)

MHF features heavily in the following sections, in many cases providing a likely route toward controllably generating
Biomimetic nano-assemblies

Cubosomes

Bicontinuous cubosomes are a class of lyotropic liquid-crystalline nanostructure strongly implicated as part of “the next generation” of soft-matter particles.21 They consist of amphiphilic bilayers draped over minimal surfaces with zero mean curvature (H) and Gaussian curvature (K) < 0, featuring two intertwined but separate aqueous networks. They are usually subdivided into three forms depending on hydration levels, each with distinct crystallographic space groups: Primitive, Schwartz diamond or, less commonly, Gyroid (Im3m, Pn3m, and Ia3d respectively).21 They typically feature monoolein and/or phytantriol lipids, though modification of the permeability and lattice parameters of the heavily folded inner membranes has been achieved by incorporation of lipids with alternative packing parameters and other desired molecular properties.52–55

Although bicontinuous cubic phases can exist in bulk, these are not suitable for most biomedical applications. Instead, an amphiphilic polymer is often used to stabilise nano-scale particle dispersions of these liquid crystalline mesophases, incorporated either during lipid self-assembly or in a subsequent, post-assembly step. The inclusion of a stabilising polymer is crucial in preventing the aggregation of cubosomal particles and is expected to alter the dimensions of the interconnected aqueous channels, making a direct comparison with larger cubic counterparts difficult.50 The presence of a polymeric corona may also be advantageous, presenting a unique opportunity to introduce functionality into these systems, overlapping cubosome design with the rich field of synthetic polymer chemistry.50,56,57

Biological membranes have been observed to adopt inverse bicontinuous cubic phases in vivo. They are thought to facilitate important biological processes such as cell fusion, division, endo/exocytosis and gas exchange in mammalian alveolar tissue.21 Synthetically mimicking these membrane structures to better understand their biological role falls in line with the overarching goals of bottom-up synthetic biology. Like their lamellar counterparts, engineered cubosomes are expected to find use in the pharmaceutical industry as delivery vehicles, their higher membrane surface area making them ideal structures for hydrophobic cargo transport and release.58–60 Some work has gone into cubosomal formulations with encapsulated gene-silencing RNA and other functional peptides, displaying exceptionally well-controlled diffusion rates.61–63 Cubosomes have been shown to provide a certain degree of in vivo protection to biomolecules that would otherwise be sensitive to enzymatic degradation, highly advantageous in the delivery of immunogenic therapeutics.62–64 Timely and impressive work from Sarkar et al. used cubosomal particles for the delivery of genetic material, attributing improved delivery efficiency to particle topology.65 There is potential for enhancing site specificity by leveraging the polymeric corona, and some preliminary work has gone into producing stimuli-responsive cubosomal particles for environmentally triggered cargo release.66–69 Sonication represents the most widely used technique in cubosome formation. A film of suitable lipid composition is generated, followed by hydration in a suitable buffer medium containing a stabilising polymer. The suspension is then homogenised via probe sonication.60,70,71 Though the technique has proved effective in reproducibly generating cubosomes of narrow size distributions, probe sonication is known to have a deleterious effect on biological material.72 As a result, alternative methods requiring lower energy input have also been explored. The most prominent of these has been solvent evaporation, whereby a volatile solvent with solubilised lipids is emulsified in a suitable aqueous buffer. Self-assembly into a cubosomal structure is initiated in a subsequent drying step.70,71 To the best of our knowledge, only one microfluidic method harnessing this emulsification approach exists, developed by Kim et al. Monollein, DOTAP and a PEGylated stabiliser were dissolved in an ethanolic stream and emulsified via chaotic mixing in an adjacent buffer stream along a microfluidic channel with herringbone features (Fig. 4). After generating 50 nm sized ethanol-in-water droplets, an off-chip evaporation step promoted the gradual fusion of those droplets followed by self-assembly into stable cubosomes ranging from 75 nm to 200 nm (bulk methods typically produce particles between 200 nm and 500 nm with PDIs > 0.1). They boast polydispersity indices as low as 0.04, and preliminary results indicate that size can be controlled by the lipid:polymer ratios and flow rates used. They go on to demonstrate the successful loading of siRNA into the cubosomal membrane in a secondary off-chip step.61 Though a promising first attempt, the additional and necessary off-chip preparations eliminate one of the key advantages of microfluidic technologies: their potential for streamlining a process, requiring minimum effort on the part of the operator. The most widely used microfluidic method for

![Fig. 4 Graphical illustration of the ethanol-in-water emulsifying microfluidic chip, designed by Kim et al.](https://example.com/image4.png)

---

This journal is © the Owner Societies 2021
generating small unilamellar vesicles (SUVs), microfluidic hydrodynamic focusing, has yet to be explored for its potential in controllably generating cubosomes. A careful consideration of other assembly routes may be necessary in designing a suitable microfluidic platform.

Hexosomes

Hexosomes represent another class of non-lamellar liquid crystal-line nanostructure with potential as functional soft-matter materials. Lipids capable of aggregating into surfaces with sufficiently negative mean curvature ($H_\parallel$) are seen to spontaneously self-assemble into inverse hexagonal phases, generally visualised as seven or more discrete tubular structures. As with cubosomes, polymeric stabilisers are used to form a corona around the hexagonal morphology of these particles, necessary to prevent aggregation through Ostwald ripening. In fact, the lipid systems used for hexosome formation are often the same as those used for cubosomes, namely phytantriol and monoolein. Preferential formation of the $H_\parallel$ phase occurs where there is pronounced hydrophobic chain “splay”, usually seen at elevated temperatures, though transitions to $H_\parallel$ can be induced under ambient temperatures through careful choice of stabilising polymer and adjustment of other environmental conditions.

Biological examples of lipid assemblies adopting an inverse hexagonal phase tend to be more elusive, though they have been proposed as important intermediate structures in enzymatic activity pathways and cell fusion events. Colloidal dispersions of hexosomes have potential use as delivery vehicles for pharmaceutical agents and biomolecules. The discontinuous nature of the closed aqueous channels in hexosomal membranes is key, allowing the slow and sustained release of cargo. This property is particularly important for the delivery of hormonal and analgesic therapeutics. Triggered release mechanisms of hexosomes tend to involve controlled phase transitions, stimulated by temperature changes and pH. Techniques used in their formation mirror those used in cubosome assembly, including emulsification followed by solvent evaporation, and lipid film hydration with a secondary probe sonication or high shear homogenisation step. Interestingly, microfluidic hydrodynamic flow focusing (MHF) has been used to successfully generate hexosomes of relatively narrow size distribution, although only one example exists to date (Fig. 5). Yaghmur et al. developed an MHF chip capable of hexosome synthesis, featuring a long serpentine channel to aid the mixing of the various amphiphilic precursors (docosahexaenoic acid monoglyceride and Pluronic F127). Unfortunately, the system did not achieve the exceptional size control typical of an MHF regime, but this will no doubt be addressed in future iterations. The very fact that a complete “on-chip” synthesis was carried out with no additional preparatory steps is significant. Despite MHF having been predominantly used to generate SUVs, this work highlights its potential to include alternative architectures and phases.

Multi-lamellar vesicles

Rather surprisingly, nano-sized multi-lamellar vesicles (MLVs) have received limited attention for their potential use as soft matter machines, hydrophobic drug delivery agents and biomimetic artificial cells bearing architectural resemblance to various cellular organelles. For clarity, it is worth defining multi-lamellar vesicles as distinct from vesosomes, the latter referring to larger membrane structures with several smaller vesicular compartments encapsulated within. MLVs are typically observed as “stacked” lamellar bilayers, occasionally exhibiting sufficiently long-range order to give quasi-Bragg peaks in small-angle X-ray scattering analysis. Deliberate MLV generation is rare, researchers citing their undesirably low core volume and stability, and a processing step (extrusion etc.) is often included to remove these layered structures and ensure the unilamellarity of produced vesicles. Large values for spontaneous curvature ($H_0$) and bending moduli, in addition to weak inter-bilayer repulsive forces, are thought to provide a thermodynamic explanation for preferential MLV formation at equilibrium, and as such their formation is highly dependent on the molecular properties of chosen amphiphiles.

To the best of our knowledge, no examples exist for the controlled preparation of either nano-scale or micron-scale MLVs using bulk methods. This is presumably due to the absence of control one has over the exact number of bilayers present in generated vesicles, understandably eliminating the possibility of designing functional MLV particles and pursuing this architecture further.

Microfluidic methods may address this shortfall, allowing enhanced control over the MLV self-assembly process, and some promising steps have already been made. Giant multi-lamellar vesicles with asymmetric bilayers were generated using a combination of droplet microfluidics and a Langmuir–Blodgett-type layering approach (Fig. 6). Lipid-stabilised water-in-oil droplets (~50 µm) were generated using a flow focusing nozzle and captured in specialised traps on the same PDMS chip. When the traps were satisfactorily occupied, a second lipid-in-oil solution was introduced, followed by an aqueous buffer wash that resulted in the self-assembly of vesicles with asymmetric bilayers. The washing steps were repeated, producing vesicles with an additional bilayer.
work represents the first successfully controlled MLV generation, and the group go on to highlight the importance of this kind of assembly in mitochondrial protein function and other in vivo processes.92 Though this method is unprecedented, the scale at which they operate does limit its potential for generating drug delivery vehicles and functional nanomaterials. However, the stepwise introduction of subsequent bilayers could in theory be re-integrated into an alternative microfluidic platform. The various mixing regimes possible within modified MHF chips could be a likely route toward nano-MLV synthesis and have been utilised in a recent paper by Ghazal et al. The group produce nano-scale (≈160 nm) MLVs using a phytantriol glyceryl dioleate-PEG12, with low dispersity values, by including a long serpentine channel. They successfully couple this production with small-angle X-ray scattering analysis to gain an insight into the mechanism of formation.93 Though a promising first step, there is limited control over the size of MLVs produced (characteristic of MHF) and each bilayer is presumably composed of the same lipid/polymer mixture.

Nanodiscs

Nanodiscs, particles consisting of a small circular region of a lipid bilayer surrounded by an amphiphilic α-helical membrane scaffold protein (MSP), have been particularly useful in the study of membrane protein structure and function. They hold significant advantages over liposomal scaffolds in that the lipid environment they provide is often more biologically relevant. Normal protein function is conserved in these scaffolds and by changing the MSP length and lipid composition, these particles have been used to incorporate a wide range of membrane proteins with diverse functionality.94,95 Widening the lipid bilayer has allowed the study of multiple proteins immobilised on one nanodisc. These larger particles have significant implications for structural biology, as laid out in a recent review by Padmanabha Das et al.96 They are generated by mixing membrane proteins and lipids, both solubilised in detergent, with an MSP of defined length, followed by detergent removal using a suitable resin. Some work has gone into directly extracting membrane proteins from cells using amphiphilic copolymers (typically styrene maleic acid and derivatives). The polymer acts as an alternative to an MSP, and the native lipid environment is preserved. This is especially useful where scaffold proteins and/or solubilising detergents are thought to adversely affect the membrane protein of interest.97,98 In addition to this, the incorporation of a synthetic component into these assemblies opens the possibility for nanodisc functionalisation.

Such research is often limited by the need for extensive optimisation of the conditions for self-assembly, necessary to best preserve protein structure and function but often time-consuming and expensive.94,99,100 This problem lends itself to adopting a microfluidic approach, as highlighted in recent work by Wade et al. (Fig. 7).100 They present a PDMS chip capable of nanodisc formation and purification. They benefit from the improved mass-transport and mixing characteristic of microfluidic flow regimes, and the inherent efficiency associated with the miniaturisation of a process. Lipids, MSPs and the membrane proteins of interest are fed into a chamber containing an immobilised detergent removal resin, then into a purification chamber with an Ni-NTA resin. They use UV-vis analysis to show the successful incorporation of Cytochrome P450 into nanodiscs as a proof of concept, acknowledging that much of the optimisation for this protein has already been accomplished. They propose the use of this platform in future optimisation studies, emphasising the potential for parallel nanodisc formation over a range of component concentrations.

As far as we are aware this is the only published example of a microfluidic platform capable of nanodisc generation. However, some microfluidic methods have been used to manipulate pre-formed nanodiscs to study various biophysical phenomena. An interesting lipid grafting technique was developed by Goluch et al. for the study of the effect of lipid composition on protein incorporation into a bilayer. Nanodiscs of varied composition were layered onto a glass slide via PDMS channels, and a fluorescently labelled annexin protein was layered on top in a criss-cross pattern.101 The formation
mechanism of copolymer stabilised nanodiscs was probed in a recent paper by Azou et al., who reconfigure a microfluidic device used for the diffusional sizing of proteins. Their work provides an insight into the solubilisation process of lipid bilayers from large unilamellar vesicles by amphiphilic copolymers, which may be useful in the future design of such nano-assemblies.

**Polymersomes**

Polymersomes can be thought of as wholly synthetic alternatives to lipidic vesicles, formed by the self-assembly of amphiphilic block copolymers in a suitable aqueous medium. These structures have been used as bio-inspired nanomachines, where a loss of the inherent biocompatibility of lipid systems can be tolerated. Though widely varied, structures tend to have much larger membrane thicknesses (5–50 nm), bending rigidity values (κ values between 35–400 kBT) and an overall improved stability compared to their lipid counterparts. The synthetic origins of polymersomes also allow for greater functional diversity making them attractive targets in drug delivery research and nanoengineering. Aligning with advances in synthetic polymer chemistry (RAFT, ATRP etc.), polymersomes responsive to light, heat, magnetism and pH have been produced. Though spherical bilayers are the most common, other unusual polymer assemblies have been observed, including worm-like structures, “patchy” or “multiple surface-domain” vesicles and “raspberry”-like polymersomes. As with lipids, the molecular properties and resulting packing parameters of polymers in aqueous media determine the phase produced, in addition to the environmental conditions under which self-assembly takes place (temperature, pressure, salt concentration, solvent etc.).

Current bulk assembly methods used to produce nano-scale polymersomes are like those seen for lipid SUV formation, including rehydration of dried polymer films followed by extrusion, shearing and probe sonication techniques. Some effort has gone into microfluidic polymersome generation at the μm scale, most notably droplet-templated methods that rely on an off-chip solvent evaporation step to induce self-assembly. However, as with lipid systems, droplet microfluidic production methods are not so easily transferred to the nano-scale. Continuous flow microfluidics have been used instead, specifically hydrodynamic focusing regimes. A standard MHF chip with micro-mixing features was used by Albuquerque et al. for the synthesis of pH-responsive nano polymersomes (Fig. 8), demonstrating the superb control (via flow rate ratio adjustment) over vesicle diameter characteristic of the method. In an interesting paper by Brown et al. the same tapered flow regime was manipulated to generate a controlled pH gradient in a microfluidic channel, triggering the self-assembly of the pH-sensitive polymer poly(2-(methacryloyloxy)ethyl phosphorylcholine)-poly(2-(diisopropylamino)ethyl methacrylate) (PMPC-b-PDPA) into polymersomes between 75 nm and 275 nm with PDI values of ~0.1. The method relies on diffusive mixing of protons but differs from MHF in that there is poor size control and both streams are aqueous, avoiding the need for potentially bio-incompatible organic solvents (EtOH, MeCN etc.). Regardless, it is an interesting proof-of-concept, and future designs may address this reduced controllability. Relatively little attention (compared to liposomes) has been given to the specific design of microfluidic platforms for nano-scale polymersome generation. Based on existing examples however, it is reasonable to suggest that well established, lipid-focused designs may be successfully repurposed for polymer vesicles with some minor alterations, and due consideration of polymer size, degrees of molecular freedom and diffusive properties.

**Perspective**

Virus-like particles (VLPs) consist of self-assembled, repeating protein subunits, often termed “coat proteins” or capsid proteins (CPs), that structurally mimic viruses, and are typically produced via modified gene expression in recombinant organisms. They have been shown to enhance and broaden immunological response when compared to singular protein/peptide immunotherapies; densely packed CPs can present multiple antigenic peptides not necessarily derived from the parent virus. This is particularly pertinent nowadays with the emergence of rapidly mutating viral strains. Their potential for use as “multi-valent vaccines” is highlighted in a recent publication from Garg et al., who present a VLP effective against Chikungunya, Japanese
Encephalitis, Yellow Fever and Zika Virus. Beyond vaccinology, they are beginning to find use in point-of-care diagnostic research and biosensings as novel delivery vehicles for small molecule drugs and gene therapies, and as biomimetic particles that could deepen our understanding of virus-cell interactions. Despite this range, research incorporating microfluidic techniques into the production and manipulation of VLPs is limited. This presents an exciting new opportunity given the benefits associated with the miniaturisation of a process, as regards cost-goods and reaction kinetics. One could envisage rapid, high throughput VLP separation, analysis, and screening on a single microfluidic platform. VLPs are successfully coupled with microfluidics in a device designed by Zang et al., where Tobacco Mosaic VLPs were immobilised on open microfluidic channel via gold–thiol (cysteine residue) interactions. VLPs were generated off-chip in recombinant E. coli, purified and fed into the device shown in Fig. 9 at low concentrations (0.2–4 mg ml\(^{-1}\)). Evenly coated surfaces were achieved passively via a capillary flow and evaporation mechanism. Each CP was genetically modified to present a FLAG-tag receptor peptide, commonly used in antibody sensing, here used to detect anti-FLAG IgG. Changes in impedance over an interdigitated Au electrode were measured as a function of target molecule (antibody) concentration (ng ml\(^{-1}\)), and a linear relationship was observed. They boast a surface functionalisation time of only 6 minutes compared to the 18 hours usually required to saturate an impedance sensor, attributing this to the local VLP concentration increase present after evaporation-capillary flow cycles. This is an impressive manipulation of microfluidic capillary action that displays the biosensing capability of VLPs, and will no doubt inspire future iterations of label-free biosensors.

### Future perspectives and concluding comments

Some interesting examples of microfluidic methods used in the controlled assembly of compositionally diverse/higher-order bio-inspired nanostructures have been presented, though the field is very much in its infancy. A growing appreciation for the potential applications of these structures as functional nano-materials is expected to coincide with the emergence of new microfluidic methods.

The use of these structures in biosensing has also been explored, and future optimisations and iterations could well see their use as novel, point-of-care diagnostic tools. The microfluidic assembly of solid/inorganic nanoparticles has been extensively reviewed elsewhere. Of note is a recent publication by Zhao et al., who outline existing platforms and give an exhaustive account of continuous flow microfluidic chip design. The process of particle assembly in these devices tends to follow similar principles to those of MHF. A route toward enhancing the complexity of biomimetic nano-assemblies may be to take inspiration from these existing designs. Chips capable of accurately tuning environmental conditions like temperature and salt concentration have already been optimised, and could well be re-engineered to controllably induce lipid/polymer-based nano-assembly phase changes, without any external preparatory steps.

As has been discussed, non-lamellar liquid crystalline nanoparticles (hexosomes and cubosomes) are likely to represent the next generation of functional drug delivery vehicles. Establishing robust microfluidic generation platforms could accelerate their incorporation into pharmaceutical formulations. The scalability of these microfluidic platforms will also determine their future in industry. Proof-of-concept research has benefited from

### Table 1 Summary of biomimetic nanoassemblies covered along with their existing examples of microfluidic technologies concerned with their generation and/or application

| Structure               | Uses                                      | Microfluidic method                                      | Ref. no. |
|-------------------------|-------------------------------------------|----------------------------------------------------------|----------|
| Cubosomes               | Drug delivery, protein crystallography,   | Micro-emulsification & solvent evaporation                | 63       |
|                         | nanomachines, biophysical studies         |                                                          |          |
| Hexosomes               | Biophysical studies, drug delivery,       | Microfluidic hydrodynamic focusing (MHF)                 | 84       |
|                         | nanomachines, gene delivery               | with long serpentine channel                             |          |
| Multi-lamellar vesicles | Biophysical studies, (potentially) site-specific drug delivery and nanomachines | MHF (nano-scale); Langmuir–Blodgett type approach (microscale) | 92 and 93 |
| Nanodiscs               | Membrane protein extraction and analysis  | Micro-mixing                                             | 100      |
| Polymersomes & hybrid vesicles | Functional and responsive nanomaterials, drug delivery | Microfluidic Hydrodynamic Focusing (MHF), 103 and 117 microfluidic pH gradient | 103 and 117 |
| Virus-like particles    | Vaccinology, immunotherapeutic delivery,  | No generation method; used as biosensor in microfluidic chip | 128      |
|                         | antigen-directed drug delivery            |                                                          |          |
photoresist soft lithography and is to date the most prolific microfabrication method. The process is time-consuming however, and requires significant operator training, making it an unlikely candidate for mass-scale production. The field may look to 3D printing techniques as an alternative. A highly automated fabrication process, 3D printing effectively eliminates human error and would assure the compliance of these devices with industrial standards. A review by Weisgrab et al. has excellently summarised recent advances in 3D microfabrication methods.\textsuperscript{137} Alongside scalability, microfluidic chip features capable of generating complex flow regimes, actuation and sensing can be more easily introduced.\textsuperscript{137,138}

As discussed by Carugo et al., an extensive study of the encapsulation efficiency of nano-assemblies produced by MHF has yet to be carried out.\textsuperscript{31} This is an essential step for the comprehensive characterisation of the technique. The necessary separation of these particles from unencapsulated material will also require attention. Current methods including dialysis and size-exclusion chromatography take place off-chip, and detract from the streamlined, ease-of-operation so integral to microfluidic technologies. We expect future technologies will take inspiration from existing microfluidic methods for nanoparticle purification. In an interesting article by Hood et al., microfluidic channels capable of dialysis/solvent exchange were introduced downstream of a standard MHF junction, allowing “on-chip” purification of loaded liposomes.\textsuperscript{139}

The problems facing the microfluidic assembly of biomimetic nano-assemblies are by no means insurmountable. The structures are rooted in a field of research that is inherently interdisciplinary and collaborative. Though current literature examples (summarised in Table 1) are limited, we expect these higher-order bioinspired particles to be at the centre of many future research efforts.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by a UKRI Future Leaders Fellowship, grant reference number MR/S031537/1 awarded to Y. E. and a departmental scholarship (Imperial College) awarded to C. P. P.

Notes and references

1 M. A. J. Roberts, R. M. Cranenburgh, M. P. Stevens and P. C. F. Oyston, Synthetic biology: biology by design, Microbiology, 2013, \textbf{159}(Pt 7), 1219–1220.
2 K. Göpfrich, I. Platzman and J. P. Spatz, Mastering Complexity: Towards Bottom-up Construction of Multifunctional Eukaryotic Synthetic Cells, Trends Biotechnol., 2018, \textbf{36}(9), 938–951.
3 A. Salehi-Reyhani, O. Ces and Y. Elani, Artificial cell mimics as simplified models for the study of cell biology, Exp. Biol. Med., 2017, \textbf{242}(13), 1309–1317.
4 B. C. Buddingh`, J. Elzinga and J. C. M. van Hest, Intracellular communication between artificial cells by allosteric amplification of a molecular signal, Nat. Commun., 2020, \textbf{11}(1), 1652.
5 A. Joseph, C. Contini, D. Cecchin, S. Nyberg, L. Ruiz-Perez, J. Gaïtitzsch and G. Battaglia, Chemotactic synthetic vesicles: Design and applications in blood-brain barrier crossing, Sci. Adv., 2017, \textbf{3}(8), e1700362.
6 Y. Elani, Interfacing Living and Synthetic Cells as an Emerging Frontier in Synthetic Biology, Angew. Chem., Int. Ed., 2021, DOI: 10.1002/anie.202006941.
7 J. Yang, A. Bahreman, G. Daudey, J. Bussmann, R. C. L. Olsthoorn and A. Kros, Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified Liposomes, ACS Cent. Sci., 2016, \textbf{2}(9), 621–630.
8 C. Peetla, A. Stine and V. Labhasetwar, Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery, Mol. Pharmaceutics, 2009, \textbf{6}(5), 1264–1276.
9 L. Sercombe, T. Veerati, F. Moheimani, S. Y. Wu, A. K. Sood and S. Hua, Advances and Challenges of Liposome Assisted Drug Delivery, Front. Pharmacol., 2015, \textbf{6}, 286.
10 M. Alavi, N. Karimi and M. Safaei, Application of Various Types of Liposomes in Drug Delivery Systems, Adv. Pharm. Bull., 2017, \textbf{7}(1), 3–9.
11 T. Osaki and S. Takeuchi, Artificial Cell Membrane Systems for Biosensing Applications, Anal. Chem., 2017, \textbf{89}(1), 216–231.
12 J. M. Thomas, M. S. Friddin, O. Ces and Y. Elani, Programming membrane permeability using integrated membrane pores and blockers as molecular regulators, Chem. Commun., 2017, \textbf{53}(91), 12282–12285.
13 E. D. Carlson, R. Gan, C. E. Hodgman and M. C. Jewett, Cell-free protein synthesis: applications come of age, Biotechnol. Adv., 2012, \textbf{30}(5), 1185–1194.
14 S. N. Lai, X. Zhou, X. Ouyang, H. Zhou, Y. Liang, J. Xia and B. Zheng, Artificial Cells Capable of Long-Lived Protein Synthesis by Using Aptamer Grafted Polymer Hydrogel, ACS Synth. Biol., 2020, \textbf{9}(1), 76–83.
15 J. P. Allen, Design of energy-transducing artificial cells, Proc. Natl. Acad. Sci. U. S. A., 2017, \textbf{114}(15), 3790–3791.
16 N. A. C. Jackson, K. E. Kester, D. Casimiro, S. Gurunathan and F. DeRosa, The promise of mRNA vaccines: a biotech and industrial perspective, npj Vaccines, 2020, \textbf{5}(1), 11.
17 A. M. Reichmuth, M. A. Oberli, A. Jaklenec, R. Langer and D. Blankschtein, mRNA vaccine delivery using lipid nanoparticles, Ther. Delivery, 2016, \textbf{7}(5), 319–334.
18 T. Trantidou, M. S. Friddin, A. Salehi-Reyhani, O. Ces and Y. Elani, Droplet microfluidics for the construction of compartmentalised model membranes, Lab Chip, 2018, \textbf{18}(17), 2488–2509.
19 X. Zhao, F. Bian, L. Sun, L. Cai, L. Li and Y. Zhao, Microfluidic Generation of Nanomaterials for Biomedical Applications, Small, 2020, \textbf{16}(9), 1901943.
20. G. C. Shearman, O. Ces, R. H. Templar and J. M. Seddon, Inverse lyotropic phases of lipids and membrane curvature, *J. Phys.: Condens. Matter*, 2006, 18(28), S1105–S1124.

21. R. Mezzenga, J. M. Seddon, C. J. Drummond, B. J. Boyd, G. E. Schröder-Turk and L. Sagalowicz, Nature-Inspired Design and Application of Lipidic Lyotropic Liquid Crystals, *Adv. Mater.*, 2019, 31(35), 1900818.

22. J. N. Israelachvili, *Intermolecular and surface forces*, Elsevier Science & Technology, 3rd edn, 2010.

23. E. Rideau, R. Dimova, P. Schwille, F. R. Wurm and K. Landfester, Liposomes and polymersomes: a comparative review towards cell mimicking, *Chem. Soc. Rev.*, 2018, 47(23), 8572–8610.

24. M. Schulz and W. H. Binder, Mixed Hybrid Lipid/Polymer Vesicles as a Novel Membrane Platform, *Macromol. Rapid Commun.*, 2015, 36(23), 2031–2041.

25. H.-O. Kim, W. Na, M. Yeom, J.-W. Lim, E.-H. Bae, G. Park and D. Song, Dengue Virus–Polymersome Hybrid Nanovesicles for Advanced Drug Screening Using Real-Time Single Nanoparticle–Virus Tracking, *ACS Appl. Mater. Interfaces*, 2020, 12(6), 6876–6884.

26. D. Khaykelson and U. Raviv, Studying viruses using solution X-ray scattering, *Biophys. Rev.*, 2020, 12(1), 41–48.

27. E. K. Sackmann, A. L. Fulton and D. J. Beebe, The present and future role of microfluidics in biomedical research, *Nature*, 2014, 507(7491), 181–189.

28. N. Convery and N. Gadegaard, 30 years of microfluidics, *Micro-Nanoeng.*, 2019, 2, 76–91.

29. N.-T. Nguyen, M. Hejazian, C. H. Ooi and N. Kashaninejad, Recent Advances and Future Perspectives on Microfluidic Liquid Handling, *Micromachines*, 2017, 8(6), 186.

30. D. van Sway and A. deMello, Microfluidic methods for forming liposomes, *Lab Chip*, 2013, 13(5), 752–767.

31. D. Carugo, E. Bottaro, J. Owen, E. Stride and C. Nastruzzi, Liposome production by microfluidics: potential and limiting factors, *Sci. Rep.*, 2016, 6(1), 25876.

32. P. Supranamiam, O. Ces and A. Salehi-Reyhani, Microfluidics for Artificial Life: Techniques for Bottom-Up Synthetic Biology, *Micromachines*, 2019, 10(5), 299.

33. S. Deshpande, Y. Caspi, A. E. C. Meijering and C. Dekker, Octanol-assisted liposome assembly on chip, *Nat. Commun.*, 2016, 7(1), 10447.

34. O. Stauffer, M. Schröter, I. Platzman and J. P. Spatz, Bottom-Up Assembly of Functional Intracellular Synthetic Organelles by Droplet-Based Microfluidics, *Small*, 2020, 1906424.

35. N.-N. Deng, M. Yelleswarapu, L. Zheng and W. T. S. Huck, Microfluidic Assembly of Monodisperse Vesosomes as Artificial Cell Models, *J. Am. Chem. Soc.*, 2017, 139(2), 587–590.

36. P. Vega-Vásquez, N. S. Mosier and J. Irudayaraj, Nanoscale Drug Delivery Systems: From Medicine to Agriculture, *Front. Biogen. Biotechnol.*, 2020, 8, 79.

37. S. G. M. Ong, M. Chitneni, K. S. Lee, L. C. Ming and K. H. Yuen, Evaluation of Extrusion Technique for Nanosizing Liposomes, *Pharmaceutics*, 2016, 8(4), 36.

38. A. Wagner and K. Vorauer-Uhl, Liposome technology for industrial purposes, *J. Drug Delivery*, 2011, 2011, 591325.

39. Y. Elani, X. C. I. Solvas, J. B. Edel, R. V. Law and O. Ces, Microfluidic generation of encapsulated droplet interface bilayer networks (multisomes) and their use as cell-like reactors, *Chem. Commun.*, 2016, 52(35), 5961–5964.

40. T. Trantidou, L. Dekker, K. Polizzi, O. Ces and Y. Elani, Functionalizing cell-mimetic giant vesicles with encapsulated bacterial biosensors, *Interface Focus*, 2018, 8(5), 20180024.

41. D. R. Link, S. L. Anna, D. A. Weitz and H. A. Stone, Geometrically mediated breakup of drops in microfluidic devices, *Phys. Rev. Lett.*, 2004, 92(5), 054503.

42. A. M. Gañán-Calvo, R. González-Prieto, P. Riesco-Chueca, M. A. Herrada and M. Flores-Mosquera, Focusing capillary jets close to the continuum limit, *Nat. Phys.*, 2007, 3(10), 737–742.

43. L. Brown, S. L. McArthur, P. C. Wright, A. Lewis and G. Battaglia, Polymersome production on a microfluidic platform using pH sensitive block copolymers, *Lab Chip*, 2010, 10(15), 1922–1928.

44. M. Lu, A. Ozcelik, C. L. Grigsby, Y. Zhao, F. Guo, K. W. Leong and T. J. Huang, Microfluidic Hydrodynamic Focusing for Synthesis of Nanomaterials, *Nanotechnology*, 2016, 11(6), 778–792.

45. J. P. Golden, G. A. Justin, M. Nasir and F. S. Ligler, Hydrodynamic focusing – a versatile tool, *Anal. Bioanal. Chem.*, 2012, 402(1), 325–335.

46. D. R. Mott, J. P. B. Howell, J. P. Golden, C. R. Kaplan, F. S. Ligler and E. S. Oran, Toolbox for the design of optimised microfluidic components, *Lab Chip*, 2006, 6(4), 540–549.

47. R. R. Hood and D. L. DeVoe, High-Throughput Continuous Flow Production of Nanoscale Liposomes by Microfluidic Vertical Flow Focusing, *Small*, 2015, 11(43), 5790–5799.

48. D. Conchouso, D. Castro, S. A. Khan and I. G. Foulds, Three-dimensional parallelization of microfluidic droplet generators for a litre per hour volume production of single emulsions, *Lab Chip*, 2014, 14(16), 3011–3020.

49. T. Nisikaso and T. Torii, Microfluidic large-scale integration on a chip for mass production of monodispersive droplets and particles, *Lab Chip*, 2008, 8(2), 287–293.

50. H. M. G. Barriga, M. N. Holme and M. M. Stevens, Cubosomes: The Next Generation of Smart Lipid Nanoparticles?, *Angew. Chem., Int. Ed.*, 2019, 58(10), 2958–2978.

51. Z. A. Almsherqi, S. D. Kohlwein and Y. Deng, Cubic membranes: a legend beyond the Flatland* of cell membrane organisation, *J. Cell Biol.*, 2006, 173(6), 839–844.

52. S. J. Fraser, X. Mulet, A. Hawley, F. Separovic and A. Polyzois, Controlling nanostructure and lattice parameters of the inverse bicontinuous cubic phases in functionalised phytantriol dispersions, *J. Colloid Interface Sci.*, 2013, 408, 117–124.

53. W. Sun, J. J. Vallooran, A. Zabara and R. Mezzenga, Controlling enzymatic activity and kinetics in swollen
mesophases by physical nano-confinement, *Nanoscale*, 2014, 6(12), 6853–6859.

54 H. M. G. Barriga, O. Ces, R. V. Law, J. M. Seddon and N. J. Brooks, Engineering Swollen Cubosomes Using Cholesterol and Anionic Lipids, *Langmuir*, 2019, 35(50), 16521–16527.

55 A. Zabara, J. T. Y. Chong, I. Martiel, L. Stark, B. A. Cromer, C. Speziale and R. Mezzenga, Design of ultra-swollen lipidic mesophases for the crystallisation of membrane proteins with large extracellular domains, *Nat. Commun.*, 2018, 9(1), 544.

56 J. Y. T. Chong, X. Mulet, B. J. Boyd and C. J. Drummond, Chapter Five – Steric Stabilisers for Cubic Phase Lyotropic Liquid Crystal Nanodispersions (Cubosomes), in *Advances in Planar Lipid Bilayers and Liposomes*, ed. A. Iglic, C. V. Kulkarni and M. Rappolt, Academic Press, 2015, vol. 21, pp. 131–187.

57 J. Zhai, R. Suryadatina, B. Luan, N. Tran, T. M. Hinton, J. Ratcliffe and C. J. Drummond, Amphiphilic brush polymers produced using the RAPT polymerisation method stabilise and reduce the cell cytotoxicity of lipid lyotropic liquid crystalline nanoparticles, *Faraday Discuss.*, 2016, 191(0), 545–563.

58 C. Caltagirone, A. M. Falchi, S. Lampis, V. Lippolis, V. Meli, M. Monduzzi and S. Murgia, Cancer-Cell-Targeted Theranostic Cubosomes, *Langmuir*, 2014, 30(21), 6228–6236.

59 I. D. Azmi, S. M. Moghimi and A. Yaghmur, Cubosomes and hexosomes as versatile platforms for drug delivery, *Ther. Delivery*, 2015, 6(12), 1347–1364.

60 N. M. Lakshmi, P. R. Yalavarthi, H. C. Vadamuduri, J. Thanniru, G. Yaga and H. Kanishka, Cubosomes as targeted drug delivery systems – a pharmaceutical approach, *Curr. Drug Discovery Technol.*, 2014, 11(3), 181–188.

61 L. Boge, H. Byssel, L. Ringstad, D. Wennman, A. Umerska, V. Cassisa and M. Andersson, Lipid-Based Liquid Crystals As Carriers for Antimicrobial Peptides: Phase Behavior and Antimicrobial Effect, *Langmuir*, 2016, 32(17), 4217–4228.

62 S. B. Rizwan, W. T. McBurney, K. Young, T. Hanley, B. J. Boyd, T. Rades and S. Hook, Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses, *J. Controlled Release*, 2013, 165(1), 16–21.

63 H. Kim, J. Sung, Y. Chang, A. Alfeche and C. Leal, Microfluidics Synthesis of Gene Silencing Cubosomes, *ACS Nano*, 2018, 12(9), 9196–9205.

64 L. Boge, K. L. Browning, R. Nordström, M. Campana, L. S. E. Damgaard, J. Seth Caous and M. Andersson, Peptide-Loaded Cubosomes Functioning as an Antimicrobial Unit against Escherichia coli, *ACS Appl. Mater. Interfaces*, 2019, 11(24), 21314–21322.

65 S. Sarkar, N. Tran, S. K. Soni, Z. Naza, C. J. Drummond and C. E. Conn, Cuboplex-Mediated Nonviral Delivery of Functional siRNA to Chinese Hamster Ovary (CHO) Cells, *ACS Appl. Mater. Interfaces*, 2021, 13(2), 2336–2345.

66 N. R. Rarokar, S. D. Saoji, N. A. Raut, J. B. Taksande, P. B. Khedekar and V. S. Dave, Nanostructured Cubosomes in a Thermoresponsive Depot System: An Alternative Approach for the Controlled Delivery of Docetaxel, *AAPS PharmSciTech*, 2016, 17(2), 436–445.

67 E. Bukusoglu, X. Wang, J. A. Martinez-Gonzalez, J. J. de Pablo and N. L. Abbott, Stimuli-Responsive Cubosomes Formed from Blue Phase Liquid Crystals, *Adv. Mater.*, 2015, 27(43), 6892–6898.

68 S. Murgia, S. Bonacchi, A. M. Falchi, S. Lampis, V. Lippolis, V. Meli and C. Caltagirone, Drug-Loaded Fluorescent Cubosomes: Versatile Nanoparticles for Potential Theranostic Applications, *Langmuir*, 2013, 29(22), 6673–6679.

69 O. Mertins, P. D. Mathews and A. Angelova, Advances in the Design of pH-Sensitive Cubosome Liquid Crystalline Nanocarriers for Drug Delivery Applications, *Nanomaterials*, 2020, 10(5), 963.

70 Z. Yang, X. Peng, Y. Tan, M. Chen, X. Zhu, M. Feng and C. Wu, Optimisation of the Preparation Process for an Oral Phytantriol-Based Amphotericin B Cubosomes, *J. Nanomater.*, 2011, 2011, 308016.

71 M. A. Ali, S. Noguchi, Y. Iwao, T. Oka and S. Itai, Preparation and Characterisation of SN-38-Encapsulated Phytantriol Cubosomes Containing 2-Monoglyceride Additives, *Chem. Pharm. Bull.*, 2016, 64, 577–584.

72 P. B. Stathopoulos, G. A. Scholz, Y.-M. Hwang, J. A. O. Rumfeldt, J. R. Lepock and E. M. Meiering, Sonication of proteins causes formation of aggregates that resemble amyloid, *Protein Sci.*, 2004, 13(11), 3017–3027.

73 D.-H. Kim, S. Lim, J. Shim, J. E. Song, J. S. Chang, K. S. Jin and E. C. Cho, A Simple Evaporation Method for Large-Scale Production of Liquid Crystalline Lipid Nanoparticles with Various Internal Structures, *ACS Appl. Mater. Interfaces*, 2015, 7(36), 20438–20446.

74 S. Revathi and M. D. Dhanaraju, Hexosomes as a novel drug delivery system: A review, *Int. J. Pharmacol. Pharm.*, 2014, 6, 58–63.

75 I. D. Azmi, S. M. Moghimi and A. Yaghmur, Cubosomes and hexosomes as versatile platforms for drug delivery, *Ther. Delivery*, 2015, 6(12), 1347–1364.

76 I. A. O. Rumfeldt, J. R. Lepock and E. M. Meiering, Sonication and Characterisation of SN-38-Encapsulated Phytantriol Cubosomes Formed from Blue Phase Liquid Crystals, *Adv. Mater.*, 2015, 27(43), 6892–6898.

77 J. Jouhet, Importance of the hexagonal lipid phase in biological membrane organisation, *Front. Plant Sci.*, 2013, 4, 494.

78 S.-J. Marrink and A. E. Mark, Molecular View of Hexagonal Phase Formation in Phospholipid Membranes, *Biophys. J.*, 2004, 87(6), 3894–3900.

79 Y. Huang and S. Gui, Factors affecting the structure of lyotropic liquid crystals and the correlation between structure and drug diffusion, *RSC Adv.*, 2018, 8(13), 6978–6987.

80 I. Martiel, N. Baumann, J. J. Vallooran, J. Bergfreund, L. Sagleowicz and R. Mezzenga, Oil and drug control the release rate from lyotropic liquid crystals, *J. Controlled Release*, 2015, 204, 78–84.

81 M. A. Shetab Boushehri, D. Dietrich and A. Lamprech, Nanotechnology as a Platform for the Development of
Injectable Parenteral Formulations: A Comprehensive Review of the Know-How and State of the Art, *Pharmaceuticals*, 2020, 12(6), 510.

82 Y. Li, A. Angelova, F. Hu, V. M. Garamus, C. Peng, N. Li and A. Zou, pH Responsiveness of Hexosomes and Cubosomes for Combined Delivery of Brucite javanica Oil and Doxorubicin, *Langmuir*, 2019, 35(45), 14532–14542.

83 Y. Chen, P. Ma and S. Gui, Cubic and Hexagonal Liquid Crystals as Drug Delivery Systems, *BioMed Res. Int.*, 2014, 2014, 815981.

84 A. Yaghmur, A. Ghazal, R. Ghazal, M. Dimaki and W. E. Svendsen, A hydrodynamic flow focusing microfluidic device for the continuous production of hexosomes based on docosahexaenoic acid monoglyceride, *Phys. Chem. Chem. Phys.*, 2019, 21(24), 13005–13013.

85 D. Vorselem, M. Marchetti, C. López-Iglesias, P. J. Peters, W. H. Roos and G. J. L. Wuite, Multi-lamellar nanovesicles show distinct mechanical properties depending on their degree of lamellarity, *Nanoscale*, 2018, 10(11), 5318–5324.

86 P. Lajoie, G. Guay, J. W. Dennis and I. R. Nabi, The lipid composition of autophagous vacuoles regulates expression of multimamellar bodies, *J. Cell Sci.*, 2005, 118(9), 1991.

87 V. E. Paquet, R. Lessire, F. Domergue, L. Fouillen, G. Filion, A. Sedighi and S. J. Charette, Lipid Composition of Multi-lamellar Bodies Secrated by Reveals Their Amoe bal Origin, *Eukaryotic Cell*, 2013, 12(10), 1326.

88 A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran, S. W. Joo, N. Zarghami, Y. Hanifehpour and K. Nejati-Koshki, Liposome: classification, preparation, and applications, *Nanoscale Res. Lett.*, 2013, 8(1), 102.

89 J. A. Bouwstra, G. S. Gooris, W. Bras and H. Talsma, Small angle X-ray scattering: possibilities and limitations in characterisation of vesicles, *Chem. Phys. Lipids*, 1993, 64(1–3), 83–98.

90 J. Peters, J. Marion, F. J. Becher, M. Trapp, T. Gutberlet, D. J. Bicout and T. Heimburg, Thermodynamics of lipid multi-lamellar vesicles in presence of sterols at high hydrostatic pressure, *Sci. Rep.*, 2017, 7(1), 15339.

91 D. D. Lasic, The mechanism of vesicle formation, *Biochem. J.*, 1988, 256(1), 1–11.

92 S. Matosovic and B. M. Paegel, Layer-by-layer cell membrane assembly, *Nat. Chem.*, 2013, 5(11), 958–963.

93 A. Ghazal, M. Gontsariak, J. P. Kutter, J. P. Lafleur, D. Ahmadvand, A. Labrador and A. Yaghmur, Microfluidic Platform for the Continuous Production and Characterisation of Multi-lamellar Vesicles: A Synchrotron Small-Angle X-ray Scattering (SAXS) Study, *J. Phys. Chem. Lett.*, 2017, 8(1), 73–79.

94 I. G. Denisov and S. G. Sligar, Nanodiscs in Membrane Biochemistry and Biophysics, *Chem. Rev.*, 2017, 117(6), 4669–4713.

95 I. G. Denisov and S. G. Sligar, Nanodiscs for structural and functional studies of membrane proteins, *Nat. Struct. Mol. Biol.*, 2016, 23(6), 481–486.

96 K. M. Padmanabha Das, W. M. Shih, G. Wagner and M. L. Nasr, Large Nanodiscs: A Potential Game Changer in Structural Biology of Membrane Protein Complexes and Virus Entry, *Front. Bioeng. Biotechnol.*, 2020, 8, 539.

97 M. C. Fiori, W. Zheng, E. Kamilar, G. Simiyu, G. A. Altenberg and H. Liang, Extraction and reconstitution of membrane proteins into lipid nanodiscs encased by zwitterionic styrene-maleic amide copolymers, *Sci. Rep.*, 2020, 10(1), 9940.

98 M. C. Fiori, Y. Jiang, W. Zheng, M. Anzaldua, M. J. Borinia, G. A. Altenberg and H. Liang, Polymer Nanodiscs: Discoidal Amphiphilic Block Copolymer Membranes as a New Platform for Membrane Proteins, *Sci. Rep.*, 2017, 7(1), 15227.

99 R. Puthenveetil, K. Nguyen and O. Vinogradova, Nanodiscs and Solution NMR: preparation, application and challenges, *Nanotechnol. Rev.*, 2017, 6(1), 111–126.

100 J. H. Wade, J. D. Jones, I. L. Revordon, S. G. Sligar and R. C. Bailey, Microfluidic platform for efficient Nanodisc assembly, membrane protein incorporation, and purification, *Lab Chip*, 2017, 17(17), 2951–2959.

101 E. D. Goluch, A. W. Shaw, S. G. Sligar and C. Liu, Microfluidic patterning of nanodisc lip bilayers and multi-plexed analysis of protein interaction, *Lab Chip*, 2008, 8(10), 1723–1728.

102 M. Azouz, M. Gonin, S. Fiedler, J. Faherty, M. Decossas, C. Cullin and A. Ciaccavafa, Microfluidic diffusional sizing probes lipid nanodiscs formation, *Biochim. Biophys. Acta, Membr.*, 2020, 1862(6), 183215.

103 L. J. C. Albuquerque, V. Sincari, A. Jäger, R. Konefa, J. I. Panek, P. Černoch and E. Jäger, Microfluidic-Assisted Engineering of Quasi-Monodisperse pH-Responsive Polymersomes toward Advanced Platforms for the Intracellular Delivery of Hydrophilic Therapeutics, *Langmuir*, 2019, 35(25), 8363–8372.

104 L. D. Blackman, S. Varlas, M. C. Arno, A. Fayter, M. I. Gibson and R. K. O’Reilly, Permeable Protein-Loaded Polymersome Cascade Nanoreactors by Polymerization-Induced Self-Assembly, *ACS Macro Lett.*, 2017, 6(11), 1263–1267.

105 J. Kim and K. T. Kim, Polymersome-Based Modular Nanoreactors with Size-Selective Transmembrane Permeability, *ACS Appl. Mater. Interfaces*, 2020, 12(20), 23502–23513.

106 M. Kanamala, B. D. Palmer, S. M. F. Jamieson, W. R. Wilson and Z. Wu, Dual pH-sensitive sheddable PEG for enhanced tumor-targeted drug delivery, *Nanomedicine*, 2019, 14(15), 1971–1989.

107 H. Che and J. C. M. van Hest, Stimuli-responsive polymersomes and nanoreactors, *J. Mater. Chem.*, 2016, 4(27), 4632–4647.

108 O. Rifaie-Graham, S. Ulrich, N. F. B. Galensowska, S. Balog, M. Chami, D. Rentsch and N. Bruns, Wavelength-Selective Light-Responsive DASA-Functionalized Polymersome Nanoreactors, *J. Am. Chem. Soc.*, 2018, 140(25), 8027–8036.

109 O. Bixner, S. Kurzhals, M. Virk and E. Reinhult, Triggered Release from Thermoresponsive Polymersomes with Superparamagnetic Membranes, *Materials*, 2016, 9(1), 29.
110 J. Gaitzsch, L. Messager, E. Morecroft and W. Meier, Vesicles in Multiple Shapes: Fine-Tuning Polymersomes' Shape and Stability by Setting Membrane Hydrophobicity, *Polymers*, 2017, 9(10), 483.

111 R. Salva, J.-F. Le Meins, O. Sandre, A. Brulet, M. Schmutz, P. Guenouin and S. Lecommandoux, Polymersome Shape Transformation at the Nanoscale, *ACS Nano*, 2013, 7(10), 9298–9311.

112 Y. Men, F. Peng, Y. Tu, J. C. M. van Hest and D. A. Wilson, Methods for production of uniform small-sized polymer vesicle with rigid membrane, *Polym. Chem.*, 2016, 7(24), 3977–3982.

113 J. Leong, J. Y. Teo, V. K. Aakalu, Y. Y. Yang and H. Kong, Engineering Polymersomes for Diagnostics and Therapy, *Adv. Healthcare Mater.*, 2018, 7(8), 1701276.

114 S. T. Poschenrieder, S. K. Schiebel and K. Castiglione, Polymersomes for biotechnological applications: Large-scale production of nano-scale vesicles, *Eng. Life Sci.*, 2017, 17(1), 58–70.

115 Y. Hu and J. Pérez-Mercader, Microfluidic fabrication of polymersomes enclosing an active Belousov-Zhabotinsky (BZ) reaction: Effect on their stability of solute concentrations in the external media, *Colloids Surf.*, B, 2016, 146, 406–411.

116 J. Petit, I. Polenz, J.-C. Baret, S. Herminghaus and O. Bäumchen, Vesicles-on-a-chip: A universal microfluidic platform for the assembly of liposomes and polymersomes, *Eur. Phys. J. E: Soft Matter Biol. Phys.*, 2016, 39(6), 59.

117 L. Brown, S. L. McArthur, P. C. Wright, A. Lewis and G. Battaglia, Polymersome production on a microfluidic platform using pH sensitive block copolymers, *Lab Chip*, 2010, 10(15), 1922–1928.

118 M. Schulz and W. H. Binder, Mixed Hybrid Lipid/Polymer Vesicles as a Novel Membrane Platform, *Macromol. Rapid Commun.*, 2015, 36(23), 2031–2041.

119 J. F. Le Meins, C. Schatz, S. Lecommandoux and O. Sandre, Hybrid polymer/lipid vesicles: state of the art and future perspectives, *Mater. Today*, 2013, 16(10), 397–402.

120 H. Zhang, W. Cui, X. Qu, H. Wu, L. Qu, X. Zhang and D. A. Weitz, Photothermal-responsive nano-sized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, 116(16), 7744–7749.

121 Z. Liu, J. Qiao, Z. Niu and Q. Wang, Natural supramolecular building blocks: from virus coat proteins to viral nanoparticles, *Chem. Soc. Rev.*, 2012, 41(18), 6178–6194.

122 A. Zelitins, Construction and Characterisation of Virus-Like Particles: A Review, *Mol. Biotechnol.*, 2013, 53(1), 92–107.

123 H. K. Charlton Hume, J. Vidigal, M. J. T. Carrondo, A. P. J. Middelberg, A. Roldão and L. H. L. Lua, Synthetic biology for bioengineering virus-like particle vaccines, *Biotechnol. Bioeng.*, 2019, 116(4), 919–935.

124 A. Roldão, M. C. Mellado, L. R. Castillo, M. J. Carrondo and P. M. Alves, Virus-like particles in vaccine development, *Expert Rev. Vaccines*, 2010, 9(10), 1149–1176.

125 M. O. Mohlsen, L. Zha, G. Cabral-Miranda and M. F. Bachmann, Major findings and recent advances in virus-like particle (VLP)-based vaccines, *Semin. Immunol.*, 2017, 34, 123–132.

126 H. Garg, T. Mehmetoglu-Gurbuz and A. Joshi, Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus, *Sci. Rep.*, 2020, 10(1), 4017.

127 K. M. Ricks, C. J. Shoemaker, L. C. Dupuy, O. Flusin, M. A. Voorhees, A. N. Fulmer and R. J. Schoepp, Development of a bead-based immunoassay using virus-like particles for detection of alphavirus humoral response, *J. Virol. Methods*, 2019, 270, 12–17.

128 F. Zhang, K. Gerasopoulos, A. D. Brown, J. N. Culver and R. Ghodssi, Capillary Microfluidics-Assembled Virus-like Particle Bionanoreceptor Interfaces for Label-Free Biosensing, *ACS Appl. Mater. Interfaces*, 2017, 9(10), 8471–8479.

129 M. Zdanowicz and J. Chroboczek, Virus-like particles as drug delivery vectors, *Acta Biochim. Pol.*, 2016, 63(3), 469–473.

130 H. Petry, C. Goldmann, O. Ast and W. Lüke, The use of virus-like particles for gene transfer, *Curr. Opin. Mol. Ther.*, 2003, 5(5), 524–528.

131 E. B. Lee, J.-H. Kim, W. Hur, J. E. Choi, S. M. Kim, D. J. Park and S. K. Yoon, Liver-specific Gene Delivery Using Engineered Virus-Like Particles of Hepatitis E Virus, *Sci. Rep.*, 2019, 9(1), 1616.

132 N. F. Steinmetz, S. Lim and F. Sainsbury, Protein cages and virus-like particles: from fundamental insight to biomimetic therapeutics, *Biomater. Sci.*, 2020, 8(10), 2771–2777.

133 J. Zepeda-Cervantes, J. O. Ramirez-Jarquin and L. Vaca, Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs, *Front. Immunol.*, 2020, 11, 1100.

134 E. M. Chan, A. P. Alivisatos and R. A. Mathies, High-Temperature Microfluidic Synthesis of CdSe Nanocrystals in Nanoliter Droplets, *J. Am. Chem. Soc.*, 2011, 133(40), 13854–13861.

135 M. J. Kennedy, H. D. Ladouceur, T. Moeller, D. Kirui and C. A. Batt, Analysis of a laminar-flow diffusional mixer for directed self-assembly of liposomes, *Biomicrofluidics*, 2012, 6(4), 44119.

136 B. W. Muir, G. Zhen, P. Gunatillake and P. G. Hartley, Salt Induced Lamellar to Bicontinuous Cubic Phase Transitions in Cationic Nanoparticles, *J. Phys. Chem. B*, 2012, 116(11), 3551–3556.

137 G. Weisgrab, A. Ovsianikov and P. F. Costa, Functional 3D Printing for Microfluidic Chips, *Adv. Mater. Technol.*, 2019, 4(10), 1900275.

138 A. Waldbaur, H. Rapp, K. Länge and B. E. Rapp, Let there be chip—towards rapid prototyping of microfluidic devices: one-step manufacturing processes, *Anal. Methods*, 2011, 3(12), 2681–2716.

139 R. R. Hood, W. N. Vreeland and D. L. DeVoe, Microfluidic remote loading for rapid single-step liposomal drug preparation, *Lab Chip*, 2014, 14(17), 3359–3367.